Seattle Genetics (SGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Genetics (SGEN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (18)	4/1/2002 7:16:23 PM
From: mopgcw	of 161

Seattle Genetics Names H. Perry Fell Chairman DOW JONES NEWSWIRES BOTHELL, Wash. -- Seattle Genetics Inc. (SGEN) named Chief Executive H. Perry Fell to the additional post of chairman. In a press release Monday, the biotechnology company said Fell replaces Charles Waite, who will remain a director. Seattle Genetics also said director Louis Bock won't seek re-election to the board in 2002 in order to spend more time with BA Venture Partners, where he is managing director. A spokeswoman declined to comment on whether the company plans to fill the seat once Bock steps down. The annual stockholders meeting is scheduled for May. The company, which had revenue of $274,000 in 2001, also named Eric Dobmeier general counsel. Company Web site: seattlegenetics.com -Tim Paradis; Dow Jones Newswires; 201-938-5400 (CORRECTED 05:31 PM) Seattle Genetics Inc. (SGEN) had revenue of $274,000 in 2001. (An item published at 3:07 p.m. EST incorrectly reported the figure as $274 million.)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next